Prot #2215-CL-0201: A Phase 3 Multicenter, Open-label, Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not

Project: Research project

Project Details

StatusActive
Effective start/end date11/18/1611/18/22

Funding

  • Astellas Pharma Global Development, Inc. (Prot #2215-CL-0201)